Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer

Journal of the National Cancer Institute

Volumn 90, Issue 16, 1998, Pages 1205-1211

  Budman, Daniel R ^a   Berry, Donald A ^b   Cirrincione, Constance T ^c   Henderson, I Craig ^d   Wood, William C ^e   Weiss, Raymond B ^f   Ferree, Carolyn R ^g   Muss, Hyman B ^h   Green, Mark R ⁱ   Norton, Larry ^j   Frei III, Emil ^k  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Cancer Leukemia Grp B Stat Ctr   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CALGB   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF VERMONT   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0032547342     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.16.1205     Document Type: Article

References (30)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992:339:71-85.
2. Goldhirsch A. Wood WC, Senn HJ. Glick JH, Gelber RD. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1995:87:1441-5.
3. Bonadonna G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 1992:52:2127-37.
4. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981:304:10-5.
5. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986:4: 1162-70.
6. Frei E 3d, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980;69:585-94.
7. Frei E 3d, Cucchi CA, Rosowsky A. Tantravahi R. Bernai S. Ervin TJ. et al. Alkylating agent resistance: in vitro studies with human cell lines. Proc Natl Acad Sci U S A 1985;82:2158-62.
8. Budman DR, Korzun AH, Aisner J, Younger J, Silver R, Costanza M, et al. A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group: CALGB 8443. Cancer Invest 1990;8:571-5.
9. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, nodepositive breast carcinoma. N Engl J Med 1994;330:1253-9.
10. Leivonen MK, Saario IA, Peltokallio P, Tuominen L, Kalima TV. A suggested follow-up time for breast cancer patients. Br J Cancer 1986;54: 837-40.
11. Fleming ID, Cooper JS, Henson DE, Hutter RV, Kennedy BJ, Murphy GP, et al, editors. Breast. AJCC cancer staging handbook. From the AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven; 1998. p. 159-70.
12. Rosner GL, Hargis JB, Hollis DR, Budman DR, Weiss RB, Henderson IC, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from Cancer and Leukemia Group B Study 8541. J Clin Oncol 1996;14:3000-8.
13. Cox DR. Regression models and life-tables. J R Stat Soc (B) 1972;34: 187-220.
14. Peto R, Peto J. Asymptomatically efficient rank invariant test procedures. J R Stat Soc (A) 1972;135:185-98.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
16. DeGroot MH. Probability and statistics. 2nd ed. Reading (MA): Addison-Wesley Publishing Co.; 1986. p. 435.
17. Mantel N, Haenszel W. Statistical analysis of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
18. Fisher ER, Anderson S, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer 1993;71: 2507-14.
19. Chapman JA, Trudeau ME, Pritchard KI, Sawka CA, Mobbs BG, Hanna WM, et al. A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancer. Breast Cancer Res Treat 1992;22:263-72.
20. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-46.
21. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, Gelber RD, Rudenstam CM, Collins J, et al. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Ann Oncol 1994;5: 717-24.
22. Gusterson BA. Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erb-B-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;10:1049-56.
23. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
24. Dimitrov N, Anderson S, Fisher B, Redmond C, Wickerham DL, Pugh R, et al. Dose intensification and increased dose of adjuvant chemotherapy for breast cancer (BC): findings from NSABP B-22 [abstract]. Proc ASCO 1994;13:A58.
25. D'Incalci M, Mantovani A, Garattini S. Heterogeneity of cancer cells. Serono Symp Publ 95. New York: Raven Press; 1993. p. 1-142.
26. Carpenter JT, Lee J. Influence of total dose, dose intensity, and dosing to individual tolerance on outcome of adjuvant chemotherapy (CT) for breast cancer [abstract]. Proc ASCO 1992;11:A95.
27. Fisher B, Sherman B, Rockette H, Redmond C, Margolese R, Fisher ER. L-Phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of disease-free survival with depression of ovarian function. National Surgical Adjuvant Project for Breast and Bowel Cancers. Cancer 1979;44: 847-57.
28. Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Zambetti M, et al. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 1985;5:95-115.
29. Bianco AR, De Placido S, Perrone F, Carlomagno C, De Laurentiis M, Del Mastro L, et al. Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer. Ann N Y Acad Sci 1993;698: 330-8.
30. Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1996;348: 1189-96.